Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Cefiderocol-Based Combination Therapy for “Difficult-to-Treat” Gram-Negative Severe Infections: Real-Life Case Series and Future Perspectives
Davide Fiore Bavaro, Alessandra Belati, Lucia Diella, et al.
Antibiotics (2021) Vol. 10, Iss. 6, pp. 652-652
Open Access | Times Cited: 75

Showing 1-25 of 75 citing articles:

Cefiderocol- Compared to Colistin-Based Regimens for the Treatment of Severe Infections Caused by Carbapenem-Resistant Acinetobacter baumannii
Marco Falcone, Giusy Tiseo, Alessandro Leonildi, et al.
Antimicrobial Agents and Chemotherapy (2022) Vol. 66, Iss. 5
Open Access | Times Cited: 144
Acinetobacter baumannii in the critically ill: complex infections get complicated
Ilaria Cavallo, Alessandra Oliva, Rebecca Pages, et al.
Frontiers in Microbiology (2023) Vol. 14
Open Access | Times Cited: 55
A review of the mechanisms that confer antibiotic resistance in pathotypes of E. coli
Sina Nasrollahian, Jay P. Graham, Mehrdad Halaji
Frontiers in Cellular and Infection Microbiology (2024) Vol. 14
Open Access | Times Cited: 35
Impact of SARS-CoV-2 Epidemic on Antimicrobial Resistance: A Literature Review
Francesco Vladimiro Segala, Davide Fiore Bavaro, Francesco Di Gennaro, et al.
Viruses (2021) Vol. 13, Iss. 11, pp. 2110-2110
Open Access | Times Cited: 98
New Drugs for the Treatment of Pseudomonas aeruginosa Infections with Limited Treatment Options: A Narrative Review
Angela Raffaella Losito, Francesca Raffaelli, Paola Del Giacomo, et al.
Antibiotics (2022) Vol. 11, Iss. 5, pp. 579-579
Open Access | Times Cited: 59
Thiazole derivatives in medicinal chemistry: Recent advancements in synthetic strategies, structure activity relationship and pharmacological outcomes
Atamjit Singh, Danish Malhotra, Karanvir Singh, et al.
Journal of Molecular Structure (2022) Vol. 1266, pp. 133479-133479
Closed Access | Times Cited: 52
New Antibiotics for Hospital-Acquired Pneumonia and Ventilator-Associated Pneumonia
Matteo Bassetti, Alessandra Mularoni, Daniele Roberto Giacobbe, et al.
Seminars in Respiratory and Critical Care Medicine (2022) Vol. 43, Iss. 02, pp. 280-294
Open Access | Times Cited: 47
Treatment of critically ill patients with cefiderocol for infections caused by multidrug-resistant pathogens: review of the evidence
Pierluigi Viale, Christian E. Sandrock, Paula Ramírez, et al.
Annals of Intensive Care (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 29
Cefiderocol-Based versus Colistin-Based Regimens for Severe Carbapenem-Resistant Acinetobacter baumannii Infections: A Propensity Score-Weighted, Retrospective Cohort Study during the First Two Years of the COVID-19 Pandemic
Maria Mazzitelli, Darío Gregori, Lolita Sasset, et al.
Microorganisms (2023) Vol. 11, Iss. 4, pp. 984-984
Open Access | Times Cited: 27
Antibiotic Treatment of Carbapenem-Resistant Acinetobacter baumannii Infections in View of the Newly Developed β-Lactams: A Narrative Review of the Existing Evidence
Francesca Serapide, Maurizio Guastalegname, Sara Palma Gullì, et al.
Antibiotics (2024) Vol. 13, Iss. 6, pp. 506-506
Open Access | Times Cited: 11
Real-life experience with compassionate use of cefiderocol for difficult-to-treat resistant Pseudomonas aeruginosa (DTR-P) infections
Marianna Meschiari, Sara Volpi, Matteo Faltoni, et al.
JAC-Antimicrobial Resistance (2021) Vol. 3, Iss. 4
Open Access | Times Cited: 53
Antibiotic Approvals in the Last Decade: Are We Keeping Up With Resistance?
Elias B. Chahine, John A. Dougherty, Krisy‐Ann Thornby, et al.
Annals of Pharmacotherapy (2021) Vol. 56, Iss. 4, pp. 441-462
Closed Access | Times Cited: 49
COVID-19 and Antimicrobial Resistance: Data from the Greek Electronic System for the Surveillance of Antimicrobial Resistance—WHONET-Greece (January 2018–March 2021)
Michalis Polemis, Georgia Mandilara, Όλγα Παππά, et al.
Life (2021) Vol. 11, Iss. 10, pp. 996-996
Open Access | Times Cited: 42
Cefiderocol for the Treatment of Multidrug-Resistant Gram-Negative Bacteria: A Systematic Review of Currently Available Evidence
Chuanhai Wang, Deqing Yang, Yifan Wang, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 37
Prospective role of cefiderocol in the management of carbapenem-resistant Acinetobacter baumannii infections: Review of the evidence
Marin H. Kollef, Hervé Dupont, David E. Greenberg, et al.
International Journal of Antimicrobial Agents (2023) Vol. 62, Iss. 2, pp. 106882-106882
Open Access | Times Cited: 19
Clinical effectiveness of cefiderocol for the treatment of bloodstream infections due to carbapenem-resistant Acinetobacter baumannii during the COVID-19 era: a single center, observational study
Alessandra Oliva, L Liguori, S. Covino, et al.
European Journal of Clinical Microbiology & Infectious Diseases (2024) Vol. 43, Iss. 6, pp. 1149-1160
Open Access | Times Cited: 6
Treatment of infections caused by carbapenem-resistant Acinetobacter baumannii
Siqin Zhang, Lingfang Di, Qi Yan, et al.
Frontiers in Cellular and Infection Microbiology (2024) Vol. 14
Open Access | Times Cited: 6
Intravenous Fosfomycin: A Potential Good Partner for Cefiderocol. Clinical Experience and Considerations
Andrea Marıno, Stefano Stracquadanio, Edoardo Campanella, et al.
Antibiotics (2022) Vol. 12, Iss. 1, pp. 49-49
Open Access | Times Cited: 22
Clinical efficacy and safety of cefiderocol for resistant Gram-negative infections: a real-life, single-centre experience
Arta Karruli, Alessia Massa, Roberto Andini, et al.
International Journal of Antimicrobial Agents (2023) Vol. 61, Iss. 2, pp. 106723-106723
Closed Access | Times Cited: 15
Real-Life Data on the Effectiveness and Safety of Cefiderocol in Severely Infected Patients: A Case Series
Ángel Marcos‐Fendián, Marta Albanell‐Fernández, Montse Tuset, et al.
Infectious Diseases and Therapy (2023) Vol. 12, Iss. 4, pp. 1205-1216
Open Access | Times Cited: 14
Carbapenem-Resistant Acinetobacter spp Infection in Critically Ill Patients With Limited Treatment Options: A Descriptive Study of Cefiderocol Therapy During the COVID-19 Pandemic
Maddalena Giannella, Stefano Verardi, Andreas Karas, et al.
Open Forum Infectious Diseases (2023) Vol. 10, Iss. 7
Open Access | Times Cited: 14
Cefiderocol Efficacy in a Real-Life Setting: Single-Centre Retrospective Study
Gabriele Palermo, Alice Annalisa Medaglia, Luca Pipitò, et al.
Antibiotics (2023) Vol. 12, Iss. 4, pp. 746-746
Open Access | Times Cited: 13
Innovative Antibiotic Therapies for Carbapenem-Resistant Gram-Negative Bacterial Infections: Clinical Efficacy, Safety, and Comparative Studies
Majid Eslami, Amirabbas Safaripour, Seyedeh Zahra Banihashemian, et al.
Microorganisms (2025) Vol. 13, Iss. 2, pp. 295-295
Open Access
Combating Metallo-β-Lactamase-Producing Pseudomonas aeruginosa: The Fractional Inhibitory Concentration Index as a Tool to Evaluate Antibiotic Synergy
Guido Granata, Carolina Venditti, Claudia Rotondo, et al.
Antibiotics (2025) Vol. 14, Iss. 2, pp. 210-210
Open Access
Colistin Treatment Outcomes in Gram-Negative Bacterial Infections in the Northeast of Romania: A Decade of Change Through Pandemic Challenges
Mădălina Alexandra Vlad, Luminiţa Smaranda Iancu, Olivia Dorneanu, et al.
Antibiotics (2025) Vol. 14, Iss. 3, pp. 275-275
Open Access
Page 1 - Next Page

Scroll to top